The medicine worked incredibly well, lowering low-density lipoprotein (LDL), the bad cholesterol, by 70%.
FORBES: How A Mourning Entrepreneur And A Dogged Doctor Rescued A Rare Disease Drug
Torcetrapib aims to raise good cholesterol, or high-density lipoprotein, by blocking the cholesterol ester transfer protein.
High-density lipoprotein, better known as HDL or "good cholesterol, " has become a medical mainstay.
Most of the time low-density lipoprotein (LDL), better known as "bad cholesterol, " sits around doing little.
ETC-216 is a slightly different version of a protein in high-density lipoprotein, the so-called good cholesterol.
"Bad" cholesterol - or low density lipoprotein - can block arteries and cause heart disease.
For a few years it thought it had one: good cholesterol, also known as high-density lipoprotein.
Alcohol, including beer, in moderation raises high-density lipoprotein or HDL, known as good cholesterol, says Dr. R.
High-density lipoprotein is thought to carry the cholesterol from the artery wall to the liver for disposal.
"I'm confused, " he says, because reducing low-density lipoprotein (LDL), or bad cholesterol, is such a cornerstone of cardiology.
The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
Nothing on the market today increases "good cholesterol, " or high-density lipoprotein (HDL), as much as torcetrapib did in early clinical trials.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
Low-density lipoprotein, the bad cholesterol, carries cholesterol fat to the arteries, where it gets stored as plaque in the artery wall.
In 19 patients with low levels of HDL (high-density lipoprotein), the Pfizer combo raised HDL counts by 61%, with few side effects.
Big studies have shown that low HDL levels may be as important as high levels of low-density lipoprotein (LDL) in causing heart attacks.
These studies had led to new cholesterol guidelines in the U.S. that suggested lowering low-density lipoprotein (LDL), or bad cholesterol, to extemely low levels.
Vytorin lowers low-density lipoprotein (LDL) more than any other single pill.
But when Zetia was combined with a statin like Lipitor or Zocor, it lowered bad cholesterol, or low-density lipoprotein (LDL), more than anything else out there.
They know that heart disease, for example, tends to occur in patients with an overabundance of any of these things: low-density lipoprotein, triglycerides, C-reactive protein or homocysteine.
Coronary artery disease begins when excess cholesterol particles, called low-density lipoprotein particles, become lodged in the artery wall over time and get chemically damaged, or oxidized (close-up diagram).
The drug is designed to boost high-density lipoprotein (HDL), nicknamed "good cholesterol" because it appears to actually clear plaque from the arteries and reduce the risk of heart attack.
Both work by inhibiting an obscure molecule called the cholesterol ester transfer protein (CETP) that works indirectly to prevent HDL from being used to create low-density lipoprotein (LDL), the bad cholesterol.
Statins help lower low-density lipoprotein cholesterol, or "bad" cholesterol.
The most common type of cholesterol problem is a high LDL (low density lipoprotein) which is usually best treated with a statin, of which there are at least four on the market.
For patients at the highest risk of heart attack, the new guidelines suggest that "bad cholesterol, " or low-density lipoprotein (LDL), be reduced to 70 mg per deciliter--although the new guideline is optional.
Schering and Merck have defended the drugs by pointing to the mountains of evidence that support the idea that lowering low-density lipoprotein, commonly known as LDL or "bad cholesterol, " prevents heart attacks.
Researchers speculating about what went wrong thought perhaps torcetrapib made HDL that didn't work, or that HDL itself (short for high-density lipoprotein, and often called "good cholesterol") was less powerful than they thought.
For the company's finances, the most important new drug is torcetrapib, a new medicine designed to raise high-density lipoprotein (HDL), the "good cholesterol, " which is thought to help clear plaque from the arteries.
应用推荐